<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003514</url>
  </required_header>
  <id_info>
    <org_study_id>BC-NE-2</org_study_id>
    <secondary_id>CDR0000066557</secondary_id>
    <nct_id>NCT00003514</nct_id>
  </id_info>
  <brief_title>Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy</brief_title>
  <official_title>Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burzynski Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the&#xD;
      laboratory. Antineoplastons may inhibit the growth of cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating&#xD;
      patients with neuroendocrine tumor that is metastatic or unlikely to respond to surgery or&#xD;
      radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Provide treatment with antineoplastons A10 and AS2-1 for patients with metastatic or&#xD;
           incurable neuroendocrine tumors.&#xD;
&#xD;
        -  Describe response, tolerance to, and side effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive gradually escalating doses of antineoplastons A10 and AS2-1 by intravenous&#xD;
      injection 6 times daily until the maximum tolerated dose is reached.&#xD;
&#xD;
      Treatment continues for at least 2 months in the absence of unacceptable toxicity or disease&#xD;
      progression. Patients achieving complete response (CR) continue treatment for an additional 8&#xD;
      months after reaching CR.&#xD;
&#xD;
      Tumors are measured every 2 months for 1 year and then every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Islet Cell Carcinoma</condition>
  <condition>Neuroendocrine Carcinoma</condition>
  <condition>Pituitary Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antineoplaston A10</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antineoplaston AS2-1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>alternative product therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biologically based therapies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cancer prevention intervention</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>complementary and alternative therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>differentiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed incurable neuroendocrine tumor that is unlikely to respond to&#xD;
             existing therapy, meeting 1 of the following criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Disease that is not curable with surgery or radiotherapy&#xD;
&#xD;
          -  Measurable disease by MRI or CT scan&#xD;
&#xD;
          -  Tumor must be at least 2 cm&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No hepatic insufficiency&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No renal insufficiency&#xD;
&#xD;
          -  Creatinine no greater than 2.5 mg/dL&#xD;
&#xD;
          -  No history of renal conditions that contraindicate high dosages of sodium&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No history of other cardiovascular conditions that contraindicate high dosages of&#xD;
             sodium&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No serious lung disease, such as chronic obstructive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No concurrent nonmalignant systemic disease&#xD;
&#xD;
          -  Not a high medical or psychiatric risk&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 8 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior cytodifferentiating agents allowed&#xD;
&#xD;
          -  No prior antineoplastons&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislaw R. Burzynski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Burzynski Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burzynski Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055-6330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>ACTH-producing pituitary tumor</keyword>
  <keyword>prolactin-producing pituitary tumor</keyword>
  <keyword>growth hormone-producing pituitary tumor</keyword>
  <keyword>recurrent pituitary tumor</keyword>
  <keyword>TSH producing pituitary tumor</keyword>
  <keyword>nonfunctioning pituitary tumor</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>stage III Merkel cell carcinoma</keyword>
  <keyword>recurrent Merkel cell carcinoma</keyword>
  <keyword>neuroendocrine carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Islet Cell</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

